EDN1 and type 2 diabetes mellitus: Treatment with nateglinide significantly increased FMED, NO, and SOD levels both at fasting and 2 hours after glucose load in patients newly diagnosed with type 2 diabetes, (P < .001) However, ET-1 and MDA decreased significantly after treatment (P < .001).